Financial Performance - Net profit attributable to shareholders increased by 2.20% to CNY 182,313,527.36 year-on-year[10] - Operating income decreased by 3.50% to CNY 1,678,628,374.37 compared to the same period last year[10] - The net profit excluding non-recurring gains and losses decreased by 22.18% to CNY 117,226,813.13 compared to the same period last year[10] - The net profit attributable to shareholders for the first quarter is 120.058 million RMB, representing a year-on-year increase of approximately 51%[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses is 106.100 million RMB, showing a year-on-year growth of about 71%[21] - Net profit for Q1 2020 was CNY 200,641,709.18, an increase from CNY 192,211,754.22 in Q1 2019, indicating improved profitability[55] Revenue and Sales - Revenue from major brand products reached CNY 1,096,000,000, a year-on-year increase of 32.93%[15] - Sales of "Xutong" Dan Shen Chuan Xiong Injection decreased by 80.72%, impacting overall revenue significantly[14] - Total revenue for Q1 2020 was CNY 1,678,628,374.37, a decrease of 3.9% compared to CNY 1,739,453,895.72 in Q1 2019[52] - The company's operating revenue for Q1 2020 was approximately ¥123.12 million, a decrease of 23.9% compared to ¥161.76 million in Q1 2019[58] Cash Flow - Cash flow from operating activities increased by 48.44% to CNY 283,116,391.03 year-on-year[10] - The net cash flow from operating activities increased by 48.44% to ¥283,116,391.03, mainly due to reduced sales and management expenses[32] - The net cash flow from investing activities surged by 185.17% to ¥89,791,646.50, driven by the receipt of equity transfer payments[32] - The net cash flow from operating activities was $381,628,415.51, a significant increase compared to $97,600,926.42 in the previous period, indicating strong operational performance[66] Assets and Liabilities - Total assets increased by 3.26% to CNY 10,182,277,147.91 compared to the end of the previous year[10] - The company's current assets totaled CNY 5,266,602,417.57 as of March 31, 2020, compared to CNY 4,797,594,684.17 at the end of 2019, indicating an increase of about 9.76%[41] - Total liabilities increased to CNY 5,054,685,963.21 from CNY 4,917,631,823.18, representing a rise of about 2.79%[46] - The company's equity attributable to shareholders increased to CNY 4,830,859,903.29 from CNY 4,662,379,296.95, showing a growth of approximately 3.6%[46] Investments - Investment income from the transfer of shares in JHBP(CY) amounted to CNY 58,555,800 during the reporting period[20] - The company’s investment income decreased by 247.97% to ¥35,458,961.20 due to the disposal of JHBP(CY)[29] - The company completed the transfer of 24,486,666 shares of JHBP(CY) Holdings Limited for a total of $28,784,857.43[33] Shareholder Information - The company holds 97,282,881 shares in its repurchase account, accounting for 3.65% of the total share capital[24] - The largest shareholder, Kang En Bei Group Co., Ltd., holds 707,248,411 shares, representing 26.52% of the total shares, with 208,430,000 shares pledged[25] - The second-largest shareholder, Hu Jiqiang, holds 176,079,085 shares, which is 6.60% of the total shares, with 127,020,000 shares pledged[25] Other Financial Metrics - The company achieved a basic earnings per share of CNY 0.071, an increase of 2.90% year-on-year[10] - The total impact of non-recurring items on net profit is 65.087 million RMB[21] - Government subsidies recognized during the period amount to 25.323 million RMB, related to revenue[21] - Other operating income and expenses include a donation expense of 10.852 million RMB[21]

Financial Performance - Total revenue for the third quarter was CNY 5.39 billion, a decrease of 2.94% year-on-year[12] - Net profit attributable to shareholders was CNY 474.40 million, down 38.77% compared to the same period last year[12] - The basic earnings per share decreased by 36.55% to CNY 0.184[12] - Operating profit for Q3 2019 was CNY 177,422,818.46, down 34.4% from CNY 270,372,314.23 in Q3 2018[52] - Net profit attributable to shareholders for Q3 2019 was CNY 84,625,994.14, a decrease of 61.8% compared to CNY 221,536,555.29 in Q3 2018[52] - The company reported a total comprehensive income of CNY 104,661,656.07 for Q3 2019, down from CNY 225,922,313.57 in Q3 2018[54] - The company reported a significant decrease in investment income, with a loss of CNY 25,889,923.49 in Q3 2019 compared to a loss of CNY 55,231,161.50 in the same period of 2018[52] Cash Flow - Cash flow from operating activities increased by 131.26% year-on-year, reaching CNY 742.11 million[12] - The net cash flow from operating activities increased by 131.26% to RMB 742,109,409.34, primarily due to improved cash collection and reduced VAT payments[32] - The net cash flow from investing activities improved by 91.12% to -RMB 117,224,272.18, as the previous year included significant acquisition payments[32] - The net cash flow from financing activities decreased by 219.00% to -RMB 610,217,055.02, mainly due to the repurchase of bonds amounting to RMB 1,023,000,000 and increased repayment of bank loans[32] - The company reported a cash inflow of 60,000,000.00 RMB from other investment activities, indicating diversification in investment sources[63] Assets and Liabilities - As of September 30, 2019, total assets amounted to RMB 10,774,615,641.83, a slight decrease from RMB 10,839,547,777.86 at the end of 2018[38] - Total liabilities increased to RMB 5,084,786,895.59 from RMB 4,983,057,623.77, marking an increase of approximately 2.0%[42] - Total equity attributable to shareholders decreased to RMB 5,428,484,200.05 from RMB 5,693,314,289.41, a decline of approximately 4.6%[42] - Current assets increased to RMB 4,981,780,818.47 from RMB 4,852,966,836.73, reflecting a growth of approximately 2.6%[40] - Total current assets amounted to approximately CNY 4.85 billion as of January 1, 2019[68] - Total liabilities were reported at RMB 3,260,116,003.93, with current liabilities accounting for RMB 2,000,635,458.75[79] Shareholder Information - The total number of shareholders at the end of the reporting period was 113,521, with the largest shareholder, Kang En Bei Group Co., Ltd., holding 707,248,411 shares, representing 26.52%[27] - The company repurchased 97,282,881 shares, accounting for 3.65% of the total share capital[27] - The company repurchased a total of 97,282,881 shares, accounting for 3.65% of the total share capital, with a total expenditure of RMB 585,149,682.93[35] Impairment and Expenses - The company recognized goodwill impairment of CNY 79.13 million related to the acquisition of Guizhou Bait Company[20] - Financial expenses increased by 64.62% to RMB 83,780,947.95, attributed to a larger scale of interest-bearing financing[33] - The company recorded an asset impairment loss of RMB 80,284,700.50, primarily related to goodwill from the acquisition of Guizhou Bait Company[33] - The company’s total assets impairment loss for Q3 2019 was CNY 79,849,585.88, compared to CNY 5,982,357.14 in Q3 2018, indicating increased asset risk[52] Revenue Sources - Revenue from major brand projects reached CNY 3.83 billion, with stable growth in several product lines[17] - Sales of the Dan Shen Chuan Xiong injection product decreased by 8.94% year-on-year, impacting overall revenue[16] - Other income rose by 60.78% to RMB 74,280,254.99, mainly due to increased government subsidies related to revenue[33] - Government subsidies recognized in the current period related to revenue totaled ¥9,608,357.83, with a year-to-date total of ¥65,907,352.24[21] Investment and Financing - The company plans to issue up to RMB 20 billion in short-term financing notes and RMB 15 billion in medium-term notes[34] - Long-term loans increased by 117.52% to RMB 332,800,000.00, reflecting increased bank financing during the reporting period[32] - The company received 2,527,750,000.00 RMB from borrowings, an increase from 2,337,160,273.97 RMB, indicating a strategy to enhance liquidity through debt[63]

证券代码：600572 证券简称：康恩贝 公告编号：临 2019-105 浙江康恩贝制药股份有限公司 | --- | --- | |----------------------------------------------------------------------------------------|-------| | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 | | | | | | 内容的真实性、准确性和完整性承担个别及连带责任。 | | 为进一步加强与投资者的沟通交流，浙江康恩贝制药股份有限公司（以下简称"公 司"）将参加由浙江上市公司协会、深圳市全景网络有限公司共同举办的"浙江辖区上市 公司投资者网上集体接待日"活动（以下简称"本次活动"），现将有关事项公告如下： 本次活动将通过深圳市全景网络有限公司提供的网上平台，采取网络远程方式举行。 投资者可登录"投资者关系互动平台"网站(http://rs.p5w.net）参与本次投资者集体接 待日活动，活动时间为 2019 年 11 月 5 日（星期二）下午 15:30 至 17:00。届时公 ...

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 3,649,888,486.84, a decrease of 1.09% compared to CNY 3,690,217,572.97 in the same period last year[25]. - The net profit attributable to shareholders of the listed company was CNY 389,773,183.25, down 29.54% from CNY 553,210,194.18 in the previous year[25]. - The basic earnings per share were RMB 0.151, reflecting a decrease of 27.05% compared to the same period last year[30]. - The net cash flow from operating activities was RMB 416.26 million, an increase of 62.85% year-on-year[30]. - The total assets at the end of the reporting period were RMB 10.99 billion, an increase of 1.40% compared to the end of the previous year[30]. - The company reported a decrease in net assets attributable to shareholders by 6.25% to RMB 5.34 billion[30]. - The company recognized a net investment income of RMB 535,300, a significant decrease from RMB 41.72 million in the same period last year[30]. - The company achieved operating revenue of 3.65 billion yuan in the first half of 2019, a decrease of 1.09% year-on-year[58]. - The net profit attributable to shareholders was 389.77 million yuan, down 29.54% year-on-year, primarily due to increased financial expenses and reduced investment income[58]. - The company reported a significant increase in financial expenses by 171.08% due to a rise in interest expenses from increased financing[75]. Operational Changes - The company has no profit distribution plan or capital reserve transfer to share capital plan for the half-year period[8]. - There are no significant risks that materially affect the company's production and operation during the reporting period[10]. - The company has not experienced any changes in its registered address or significant operational changes during the reporting period[23]. - The financial report for the half-year period has not been audited[9]. - The company continues to focus on its core pharmaceutical business without any major strategic shifts reported[10]. Risk Management - The company has outlined various risks it may face in its operations, including industry policy risks and market risks[10]. - The company anticipates significant risks in the pharmaceutical industry, including policy risks, market risks, and product quality risks, which could impact its operations[126]. - The company will strengthen compliance and risk management to ensure stable operations and address potential impacts from regulatory changes[74]. Research and Development - The company has applied for over 200 patents, with more than 100 granted, and is currently developing nearly 20 innovative drugs[46]. - The company is actively enhancing its research and development capabilities and fostering collaboration among its teams to drive innovation[47]. - The company has launched 24 projects for consistency evaluation, with 2 projects approved in 2019, including Amoxicillin capsules and Montmorillonite powder[47]. - Research and development expenses increased by 22.94% to approximately ¥90.34 million, reflecting the company's focus on consistency evaluation of generic drugs and secondary development of leading products[75]. Marketing and Sales - The company's products are distributed through self-operated and agency marketing models, covering most regions of the country, including hospitals and retail pharmacies[39]. - The company’s marketing network covers over 300,000 retail pharmacies and hospitals nationwide, demonstrating strong market adaptability[53]. - Sales revenue from major brand products reached 2.632 billion yuan, a slight decline of 1.11% year-on-year, with some products like "Kang En Bei" brand achieving a 34.4% increase[59]. - The pharmaceutical industry accounted for 98.53% of total revenue, with sales revenue of 3.60 billion RMB, a decrease of 0.23% year-on-year, while the proportion of the pharmaceutical industry increased by 4.07 percentage points[87]. Environmental Management - The company has established a comprehensive quality management system to ensure the safety and effectiveness of its pharmaceutical products throughout the production and distribution processes[131]. - The company emphasizes safety management and has implemented a safety production responsibility system to mitigate risks associated with its operations[132]. - The company has invested approximately 1.97 million RMB in environmental protection facilities, maintaining a stable operation rate of over 98%[166]. - The company has established a wastewater treatment facility with a design capacity of 1,500 tons per day[166]. - The company has reported a total of 1,741.7 tons of hazardous waste generated in the first half of 2019, with contracts signed for proper disposal[170]. Shareholder and Capital Management - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[10]. - The company plans to repurchase shares for employee stock ownership plans and convertible bonds, with a total repurchase amount not exceeding RMB 800 million[31]. - The company paid cash dividends of 385.51 million RMB during the reporting period, impacting financing cash flow due to timing differences in profit distribution[79]. - The company issued 156.5902 million A shares to six investors, who committed not to transfer their shares for 12 months from the issuance date, which ends on January 9, 2019[141].

Financial Performance - The net profit attributable to the parent company for 2018 was RMB 803,794,506.60, with a distributable profit at the end of the year amounting to RMB 1,887,252,523.05[6]. - The total distributable profit at the end of 2018 was RMB 2,165,483,293.53, after accounting for the previous year's undistributed profit and legal reserves[6]. - The company's operating revenue for 2018 was CNY 6,786,645,292.78, representing a 28.20% increase compared to CNY 5,293,966,778.84 in 2017[27]. - The net profit attributable to shareholders for 2018 was CNY 803,794,506.60, an increase of 13.03% from CNY 711,116,240.43 in 2017[27]. - The net profit after deducting non-recurring gains and losses was CNY 756,347,021.41, which is an 8.31% increase from CNY 698,309,967.14 in 2017[27]. - The total assets at the end of 2018 were CNY 10,713,404,733.02, a 13.73% increase from CNY 9,420,221,233.95 in 2017[27]. - The basic earnings per share for 2018 was CNY 0.30, up 7.14% from CNY 0.28 in 2017[28]. - The company achieved a total revenue of 6.787 billion yuan in 2018, representing a year-on-year growth of 28.20%[61]. - The net profit attributable to shareholders was 804 million yuan, up 13.03% compared to the previous year[61]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 756 million yuan, up by 8.31% year-on-year[74]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of RMB 1.5 per 10 shares, totaling RMB 385,505,597.85, after repurchasing 97,282,881 shares for RMB 585,017,792.34[6]. - The company repurchased a total of 50,451,611 shares, accounting for 1.89% of the total share capital, with a total payment of CNY 311,364,563.44[30]. - The company repurchased 50,451,611 shares, accounting for 1.89% of the total share capital, for employee stock ownership plans and convertible bonds[110]. Risk Management - The company has not reported any significant risks that could materially affect its operations during the reporting period[10]. - The company has implemented measures to address various risks, including industry policy risks and product quality control risks[10]. Audit and Compliance - The company’s financial report has been audited by Tianjian Accounting Firm, which issued a standard unqualified audit opinion[6]. - The company has a commitment to ensuring the accuracy and completeness of its financial reports, as stated by its senior management[6]. Market and Product Development - The company plans to continue expanding its market presence and investing in new product development to drive future growth[29]. - The company focuses on pharmaceutical R&D, manufacturing, and distribution, with a product structure based on modern traditional Chinese medicine and specialty chemical drugs[41]. - The company’s product forms include over 20 types, such as tablets, capsules, injections, and syrups, targeting various therapeutic areas including cardiovascular, digestive, and respiratory diseases[43]. - The company has increased the number of brand or product series with sales revenue exceeding 500 million RMB from 2 to 3, with one product surpassing 1 billion RMB in sales in 2018[49]. - The company has applied for over 200 patents, with more than 100 granted, and is currently developing nearly 20 innovative drugs[54]. - The company’s core technologies include new techniques for extraction and separation of traditional Chinese medicine, quality control, and process control, which enhance its competitive position in the industry[54]. - The company’s well-known brands include Kang En Bei, Qian Lie Kang, and Zhen Shi Ming, with significant market shares in their respective segments[55]. Sales and Revenue Growth - The pharmaceutical industry in China achieved a main business revenue of 2,398.63 billion RMB, representing a year-on-year growth of 12.6%[45]. - The pharmaceutical industrial revenue reached 6.678 billion yuan, with a year-on-year increase of 31.70%, accounting for 98.39% of total revenue[61]. - The sales revenue of the "big brand and big variety" project reached 5.076 billion yuan, a growth of 37.15% year-on-year[63]. - The "Kang En Bei" brand intestinal inflammation series achieved sales of 668 million yuan, growing by 25.59%[63]. - The "Jin Di" brand compound fish mint syrup saw a sales increase of 100.11%, reaching 357 million yuan[63]. - The sales volume of "Dan Shen Chuan Xiong" injection reached 9.201 million units, with a revenue increase of 70.05% to 1.760 billion yuan[63]. - The company’s sales expenses increased by 49.84% to 3.42 billion RMB, indicating a significant rise in marketing efforts[75]. - The company’s R&D expenses rose by 21.37% to 183.39 million RMB, reflecting a commitment to innovation[75]. Inventory and Cash Flow - The net cash flow from operating activities for 2018 was CNY 545,776,464.50, a decrease of 23.58% compared to CNY 714,146,959.45 in 2017[27]. - The company’s cash flow from operating activities decreased by 23.58% to 545.78 million RMB, indicating potential liquidity challenges[75]. - The company's inventory management led to a reduction in stock levels, with a significant decrease in inventory for injectable products[86]. - The company reported a significant decrease in inventory levels for products such as Melatonin Sodium[88]. Research and Development - The total R&D expenditure for the period was CNY 183,388,884.77, accounting for 2.70% of total operating revenue[96]. - The number of R&D personnel was 892, representing 9.56% of the total workforce, indicating a strong focus on innovation[96]. - The company has 108 ongoing research projects, including 63 chemical drugs and 24 traditional Chinese medicines[153]. - The company is actively investing in innovative drug research and consistency evaluation to enhance its product portfolio[153]. - The company’s R&D investment in Ginkgo biloba product development was CNY 815.14 million, marking a 63.50% increase compared to the previous year[154]. Strategic Partnerships and Acquisitions - The company invested 950 million yuan in Jiahe Biopharmaceutical Co., becoming its second-largest shareholder[64]. - The company invested 300.35 million RMB to acquire a 41% stake in Jiangxi Tianshikang, achieving full ownership[68]. - The company acquired a 25.33% stake in Jiahe Biotech for a cost of RMB 95,255,000, contributing a net loss of RMB -2,349,090 since acquisition[181]. - The company acquired a 41% stake in Jiangxi Tianshikang for RMB 31,310,070, which generated a net profit of RMB 3,358,990 during the reporting period[181]. Regulatory Environment - The establishment of the National Healthcare Security Administration has initiated significant reforms in the pharmaceutical industry, emphasizing quality and cost control[121]. - The 4+7 pilot program for centralized procurement has transformed the pricing model for pharmaceuticals, benefiting high-quality and cost-effective therapeutic products[122]. - The company is actively participating in the consistency evaluation of its key products to align with national procurement initiatives[122]. - The company is conducting various studies on its key prescription drugs to comply with the new DRGs payment system being implemented by the National Healthcare Security Administration[123]. Market Trends - The pharmaceutical manufacturing industry is expected to continue growing, driven by national healthcare reforms and increasing health demands[113]. - The company is focusing on optimizing its product structure through R&D and acquisitions to enhance its competitive position in the market[117]. - The company is focusing on the development of generic drugs that are equivalent in quality and efficacy to original drugs, as per the government's policy[130].

证券简称：康恩贝 证券代码：600572 编号：临 2019—050 浙江康恩贝制药股份有限公司 | --- | |----------------------------------------------------------------------------------------| | 关于 2018 年度业绩现场说明会暨投资者接待日活动召开情况的公告 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 | | 内容的真实性、准确性和完整性承担个别及连带责任。 | 一、业绩说明会暨接待日类型 本次公司 2018 年度业绩现场说明会暨投资者接待日活动以现场交流方式举行。 二、说明会召开的时间、地点 1、会议召开时间：2019 年 5 月 16 日（周四）下午 14:00—17:00 2、会议召开地点：杭州市滨江区滨康路 568 号康恩贝中心会议室 3、召开方式：现场召开 三、公司参加人员 公司董事长胡季强先生，总裁王如伟先生，副总裁陈岳忠先生，副总裁、董事会秘书杨 俊德先生，财务总监袁振贤女士。 四、投资者参加方式 投资者以现场提问形式，就公司经营业绩和经 ...

浙江康恩贝制药股份有限公司 公司 2018 年度业绩说明会暨投资者接待日活动会议纪要 一、说明会基本情况： 时间：2019 年 5 月 16 日（周四）下午 14:00—17:00 地点：杭州市滨江区滨康路 568 号康恩贝中心会议室 参加人员：公司董事长胡季强先生，总裁王如伟先生，副总裁陈岳忠先生，副总 裁、董事会秘书杨俊德先生，财务总监袁振贤女士。天风证券、中信证券、兴业证券、 平安证券、浙商证券、东兴证券、湘财证券、申万宏源证券、财通证券、上海证券、 长城证券、华泰证券等多家机构行业研究人员和部分投资机构代表、个人投资者等共 80 余人。 二、说明会主要内容纪要： （一）会议开始，由公司董事会秘书杨俊德先生主持并致欢迎辞。 （二）首先，公司财务总监袁振贤女士就公司 2018 年度经营情况做了介绍。2018 年度，公司实现营业收入 67.87 亿元，同比增长 28.20%；归属于上市公司股东净利润 8.04 亿元，同比增长 13.03%；扣非后归属于上市公司股东净利润 7.56 亿元，同比增 长 8.31%。医药工业销售 18 年收入 66.78 亿元，同比增长 31.70%，占报告期营收的 98.39% ...

Financial Performance - The net profit attributable to the parent company for 2018 was RMB 803,794,506.60, with a total distributable profit at the end of 2018 amounting to RMB 2,165,483,293.53[8] - The company reported a retained earnings balance of RMB 1,850,357,176.03 carried over from the previous year[8] - The company's operating revenue for 2018 was CNY 6,786,645,292.78, representing a 28.20% increase compared to CNY 5,293,966,778.84 in 2017[29] - The net profit attributable to shareholders for 2018 was CNY 803,794,506.60, an increase of 13.03% from CNY 711,116,240.43 in 2017[29] - The total assets at the end of 2018 were CNY 10,713,404,733.02, a 13.73% increase from CNY 9,420,221,233.95 in 2017[29] - The basic earnings per share for 2018 was CNY 0.30, up 7.14% from CNY 0.28 in 2017[30] - The weighted average return on equity for 2018 was 13.89%, a decrease of 1.99 percentage points from 15.88% in 2017[30] - The company achieved a revenue of 6.787 billion CNY in 2018, representing a year-on-year growth of 28.20%[66] - The net profit attributable to shareholders was 804 million CNY, up 13.03% compared to the previous year[66] Dividend Distribution - The company plans to distribute a cash dividend of RMB 1.5 per 10 shares, totaling RMB 385,505,597.85, after deducting the repurchased shares from the total share capital[8] - The company has committed to maintaining compliance with regulations regarding investor protection and dividend distribution[8] Share Repurchase - The company repurchased 97,282,881 shares for a total amount of RMB 585,017,792.34, excluding transaction fees[8] - The company repurchased a total of 50,451,611 shares, accounting for 1.89% of the total share capital, with a total payment of CNY 311,364,563.44[33] - The company plans to use the repurchased shares for employee stock ownership plans and for converting convertible bonds[33] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[13] - The company has outlined various risks it may face in its operations, including industry policy risks and market risks, in its detailed risk analysis section[13] Research and Development - The company has applied for over 200 patents, with more than 100 granted, and is currently developing nearly 20 innovative drugs[54] - The company has initiated the "Innovation-Driven Development Project" in 2018, focusing on the safety, efficacy, and quality consistency of drugs, optimizing product structure, and enhancing academic promotion and new product development[130] - The company is focusing on the secondary development of major traditional Chinese medicine products to enhance quality standards and production processes[152] - Research and development investment amounted to 183.39 million RMB, representing 2.70% of operating revenue[155] Market Position and Strategy - The company has established itself as a leading player in the domestic pharmaceutical industry, ranking among the top 100 pharmaceutical companies and top 10 traditional Chinese medicine companies in China[49] - The company is actively pursuing structural reforms in the pharmaceutical sector, enhancing its core competitiveness through innovation and product optimization[48] - The company is exploring the global market for its products, leveraging the internationalization of drug registration and development processes[130] Sales and Marketing - The company expanded its sales network, covering over 300,000 retail pharmacies and nearly all hospitals nationwide[66] - The company has a strong brand portfolio, with several brands recognized as famous trademarks in China, contributing to its competitive advantage in the market[56] - The company is actively optimizing its product structure through R&D and acquisitions to enhance its competitive position in the market[120] Government Support and Industry Trends - The company received government subsidies amounting to CNY 54,582,662.05 in 2018, which were closely related to its normal business operations[37] - The pharmaceutical industry in China achieved a main business income of 23,986.3 billion RMB in 2018, reflecting a year-on-year growth of 12.6%[47] - The pharmaceutical manufacturing industry is expected to maintain high-quality growth, driven by population aging and health consumption upgrades, with broader development opportunities in 2019.[117] Financial Audits - The company’s financial report has been audited by Tianjian Accounting Firm, which issued a standard unqualified opinion[7]

Financial Performance - Operating revenue for the first quarter was ¥1,688,358,242.03, a decrease of 5.27% year-on-year, primarily due to a high revenue base from cold medicine products in the same period last year[14][15] - Net profit attributable to shareholders was ¥176,198,966.73, down 34.22% compared to the same period last year[14] - The weighted average return on equity decreased by 1.40 percentage points to 3.17%[14] - The company reported a net profit margin decline due to reduced revenue, impacting overall profitability[50] - The company reported a total of ¥1.09 billion in payable bonds, indicating a significant portion of long-term financing[71] Cash Flow - The net cash flow from operating activities increased by 49.33% year-on-year, amounting to ¥199,422,600.68[14] - Cash inflow from operating activities totaled CNY 1,956,472,434.84, an increase from CNY 1,736,204,500.08 in the previous year, representing a growth of approximately 12.67%[61] - Net cash flow from investing activities improved significantly to RMB 30,460,222.15, a 128.46% increase from a negative RMB 107,023,233.99, due to the completion of securities disposals[27] - Cash inflow from financing activities reached CNY 435,333,000.00, compared to CNY 136,620,000.00 in the prior year, marking an increase of approximately 218.5%[63] Assets and Liabilities - Total assets at the end of the reporting period reached ¥10,921,055,393.91, an increase of 1.94% compared to the end of the previous year[14] - Total liabilities increased to CNY 5,155,316,836.35 from CNY 4,920,817,677.93, reflecting a growth of 4.78%[46] - The company reported short-term borrowings of 1,280,900,000.00, indicating a significant liability position[68] - The company has a total of approximately $368.14 million in other payables, including interest payable of about $20.19 million[77] Shareholder Information - The number of shareholders at the end of the reporting period was 115,205, with the largest shareholder, 康恩贝集团有限公司, holding 707,248,411 shares, representing 26.52%[21] - The top ten shareholders collectively hold a significant portion of shares, with the top two shareholders alone accounting for 35.32% of total shares[21] - The company has no preferred shareholders as of the reporting period[24] Research and Development - The company is focusing on expanding its R&D capabilities, as indicated by the increase in prepayments for R&D expenses[25] - Research and development expenses increased to CNY 8,067,707.36 in Q1 2019 from CNY 8,799,749.89 in Q1 2018[54] Investment Activities - The company recognized an investment loss of ¥15,784,300 from its stake in Jiahe Biological Pharmaceuticals during the reporting period[17] - The company reported an investment loss of CNY -24,327,428.16 in Q1 2019, compared to a profit of CNY 74,565,811.45 in Q1 2018[58] Other Financial Metrics - Financial expenses increased by ¥20,826,800 due to a rise in bank borrowings compared to the same period last year[17] - Other income rose to RMB 33,035,891.11, reflecting a 116.81% increase from RMB 15,237,097.38, attributed to increased government subsidies[27] - The company reported a significant increase in financial expenses, totaling RMB 30,372,666.80, up 218.18% from RMB 9,545,898.99 due to increased bank borrowings[27] Company Developments - The company is actively working on the processing of industrial hemp, having received approval for its project and is in the process of upgrading production lines[33] - The company plans to acquire 100% equity of a subsidiary for RMB 30 million and will inject an additional RMB 60 million into the subsidiary[34] - The company established Yunnan Kangma Biotechnology Co., Ltd. with a registered capital of RMB 100 million, holding 30% equity[35]

证券简称：康恩贝 证券代码：600572 编号：临 2019—039 | --- | --- | |----------------------------------------------------------------------------------|--------------------------------------------| | | | | | 浙江康恩贝制药股份有限公司 | | 关于举行 2018 | 年度业绩现场说明会暨投资者接待日活动的公告 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， | | | 并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 根据中国证券监督管理委员会浙江监管局下发的《浙江辖区上市公司投资者接 待日工作指引》的要求，为进一步提高公司治理水平，加强投资者关系管理，增进 公司与广大投资者的沟通与交流，公司定于 2019 年 5 月 16 日下午举行 2018 年度业 绩现场说明会暨投资者接待日活动，就公司的经营业绩、发展战略等具体情况向投 资者进行说明，并回答投资者关心的问题。现将有关安排公告如下： ...